{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:29:42Z","timestamp":1793982582363,"version":"4.8.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thrombocytopenia in ill children is common; accurately diagnosing the underlying etiology is challenging and essential for appropriate management. Triggers for accelerated consumption of platelets are numerous; common downstream mechanisms of clearance include platelet trapping in microvascular thrombi, phagocytosis, and platelet activation. Thrombocytopenia with microangiopathic hemolytic anemia (MAHA) is frequently due to disseminated intravascular coagulation. Thrombotic microangiopathy (TMA) is a subgroup of MAHA. Specific TMA syndromes include thrombotic thrombocytopenic purpura, complement-mediated TMA (CM-TMA), and Shiga toxin\u2013mediated hemolytic uremic syndrome. Isolated thrombocytopenia is characteristic of immune thrombocytopenia; however, concomitant cytopenias are frequent in critically ill patients, making the diagnosis difficult. Immune thrombocytopenia with large vessel thrombosis is a feature of heparin-induced thrombocytopenia and antiphospholipid antibody syndrome. In addition, thrombocytopenia is common with macrophage activation, which is characteristic of hemophagocytic lymphohistiocytosis. While thrombocytopenia in ill patients can be driven by hypoproliferative processes such as myelosuppression and\/or bone marrow failure, this review will focus on consumptive thrombocytopenia due to immune and nonimmune causes.<\/jats:p>","DOI":"10.1182\/hematology.2023000465","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:11:32Z","timestamp":1702048292000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Where have all the platelets gone? HIT, DIC, or something else?"],"prefix":"10.1182","volume":"2023","author":[{"given":"Rohith","family":"Jesudas","sequence":"first","affiliation":[{"name":"St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford M.","family":"Takemoto","sequence":"additional","affiliation":[{"name":"St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"21","key":"2023120815070178000_hem2023000465C1","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2023120815070178000_hem2023000465C2","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2023120815070178000_hem2023000465C3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpeds.2014.09.017","article-title":"Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system","volume":"166","author":"Obeng","year":"2015","journal-title":"J Pediatr"},{"issue":"11","key":"2023120815070178000_hem2023000465C4","doi-asserted-by":"crossref","first-page":"e29929","DOI":"10.1002\/pbc.29929","article-title":"Application of a clinical decision rule and laboratory assays in pediatrics: adult heparin-induced thrombocytopenia","volume":"69","author":"Cohen","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2023120815070178000_hem2023000465C5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/asheducation-2011.1.162","article-title":"Heparin-induced thrombocytopenia screening and management in pediatric patients","volume":"2011","author":"Takemoto","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2023120815070178000_hem2023000465C6","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2011-11-376293","article-title":"How I treat heparin-induced thrombocytopenia","volume":"119","author":"Cuker","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2023120815070178000_hem2023000465C7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings","volume":"4","author":"Lo","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2023120815070178000_hem2023000465C8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpeds.2020.06.081","article-title":"Heparin-induced thrombocytopenia in a pediatric population: implications for clinical probability scores and testing","volume":"226","author":"Avila","year":"2020","journal-title":"J Pediatr"},{"issue":"1","key":"2023120815070178000_hem2023000465C9","first-page":"106","article-title":"Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach","volume":"40","author":"Cuker","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2023120815070178000_hem2023000465C10","first-page":"678","article-title":"Anti-heparin\/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia","volume":"100","author":"Whitlatch","year":"2008","journal-title":"Thromb Haemost"},{"issue":"8","key":"2023120815070178000_hem2023000465C11","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/blood.2020008195","article-title":"A prospective, blinded study of a PF4-dependent assay for HIT diagnosis","volume":"137","author":"Samuelson Bannow","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023120815070178000_hem2023000465C12","doi-asserted-by":"crossref","first-page":"e27619","DOI":"10.1002\/pbc.27619","article-title":"Primary immune regulatory disorders for the pediatric hematologist and oncologist: a case-based review","volume":"66","author":"Chandrakasan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"2023120815070178000_hem2023000465C13","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2023120815070178000_hem2023000465C14","doi-asserted-by":"crossref","first-page":"e28949","DOI":"10.1002\/pbc.28949","article-title":"Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children","volume":"68","author":"Siddiqui","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2023120815070178000_hem2023000465C15","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2023120815070178000_hem2023000465C16","doi-asserted-by":"crossref","first-page":"11346","DOI":"10.1182\/blood-2022-170608","article-title":"Plasmic (PLASMICkid) score for pediatric thrombotic thrombocytopenic purpura","volume":"140","author":"Rairikar","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2023120815070178000_hem2023000465C17","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2023120815070178000_hem2023000465C18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2023120815070178000_hem2023000465C19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"2023120815070178000_hem2023000465C20","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2023120815070178000_hem2023000465C21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2023120815070178000_hem2023000465C22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2023120815070178000_hem2023000465C23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi- system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"issue":"9","key":"2023120815070178000_hem2023000465C24","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1007\/s12325-022-02184-4","article-title":"The role of complement in HSCT-TMA: basic science to clinical practice","volume":"39","author":"Meri","year":"2022","journal-title":"Adv Ther"},{"issue":"4","key":"2023120815070178000_hem2023000465C25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1376153","article-title":"Spectrum of complement- mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches","volume":"40","author":"Riedl","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2023120815070178000_hem2023000465C26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"issue":"25","key":"2023120815070178000_hem2023000465C27","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood.2021012860","article-title":"Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond","volume":"139","author":"Gavriilaki","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2023120815070178000_hem2023000465C28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/17474086.2018.1500173","article-title":"Disseminated intravascular coagulation: an update on pathogenesis and diagnosis","volume":"11","author":"Levi","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"2023120815070178000_hem2023000465C29","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1038\/nrdp.2016.37","article-title":"Disseminated intravascular coagulation","volume":"2","author":"Gando","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2023120815070178000_hem2023000465C30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccc.2019.12.010","article-title":"Thrombocytopenia-associated multiple organ failure","volume":"36","author":"Nguyen","year":"2020","journal-title":"Crit Care Clin"},{"issue":"6","key":"2023120815070178000_hem2023000465C31","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.siny.2011.07.009","article-title":"Diagnosis and management of neonatal purpura fulminans","volume":"16","author":"Price","year":"2011","journal-title":"Semin Fetal Neonatal Med"},{"issue":"4","key":"2023120815070178000_hem2023000465C32","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/jth.12155","article-title":"Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines","volume":"11","author":"Wada","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2023120815070178000_hem2023000465C33","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation","volume":"86","author":"Taylor","year":"2001","journal-title":"Thromb Haemost"},{"issue":"2","key":"2023120815070178000_hem2023000465C34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/archdischild-2016-311053","article-title":"Disseminated intravascular coagulation in paediatrics","volume":"102","author":"Rajagopal","year":"2017","journal-title":"Arch Dis Child"},{"issue":"5","key":"2023120815070178000_hem2023000465C35","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/PCC.0000000000000705","article-title":"Evaluation of disseminated intravascular coagulation scores in critically ill pediatric patients","volume":"17","author":"Jhang","year":"2016","journal-title":"Pediatr Crit Care Med"},{"issue":"6","key":"2023120815070178000_hem2023000465C36","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1309\/AJCPO64IWNLYCVVB","article-title":"Evaluation of the International Society on Thrombosis and Haemostasis and institutional diagnostic criteria of disseminated intravascular coagulation in pediatric patients","volume":"139","author":"Soundar","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2023120815070178000_hem2023000465C37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600.x","article-title":"Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology","volume":"145","author":"Levi","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"2023120815070178000_hem2023000465C38","doi-asserted-by":"crossref","first-page":"e27929","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2023120815070178000_hem2023000465C39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10875-020-00789-4","article-title":"Thinking beyond HLH: clinical features of patients with concurrent presentation of hemophagocytic lymphohistiocytosis and thrombotic microangiopathy","volume":"40","author":"Gloude","year":"2020","journal-title":"J Clin Immunol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/43\/2175925\/43jesudas.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/43\/2175925\/43jesudas.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:11:47Z","timestamp":1702048307000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/43\/506434\/Where-have-all-the-platelets-gone-HIT-DIC-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000465","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}